Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 14/20 | 0.80 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.80 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.80 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.80 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.80 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.80 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.80 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.80 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.80 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1902019 | 0.90 | HDAC1 (0.97) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL30029834 | 0.89 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL29921577 | 0.89 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL1063954 | 0.89 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL675185 | 0.89 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL20163304 | 0.84 | HDAC1 (0.60) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL16016612 | 0.84 | HDAC1 (0.84) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL29736959 | 0.84 | HDAC1 (0.89) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL12125319 | 0.83 | HDAC1 (0.83) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL24881434 | 0.83 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC4HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141965-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141965-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SPINT2, SERPINB1 | HDAC1 643/4885HDAC3 1104/4885HDAC2 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.